跳转到主要内容

Cochrane shows support for WHO-ICMRA statement on transparency and data integrity

This news item is more than 4 years old.
Image
"COVID-19 has highlighted the importance of timely access to detailed clinical trial data for building public trust and for assessing the quality of studies."

The World Health Organization (WHO) and International Coalition of Medicines Regulatory Authorities (ICMRA) have issued a joint statement calling on the pharmaceutical industry to increase transparency and access to clinical data for all new medicines and vaccines.

Dr Karla Soares-Weiser, Editor in Chief of The Cochrane Library and Acting CEO of Cochrane, said:

“Cochrane is an advocate for greater clinical trial transparency and supports the statement issued by WHO and ICMRA calling on the pharmaceutical industry to provide wider access to research data for new medicines. 

COVID-19 has highlighted the importance of timely access to detailed clinical trial data for building public trust and for assessing the quality of studies. Sharing this information has clear benefits to public health and research integrity.

When trial results are not published, or are overly redacted, the ability to make truly evidence-informed decisions about healthcare is jeopardised. This puts people at risk of harm and contributes to research waste.”

引用的多媒体源缺失,需要重新嵌入。

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置